(EMAILWIRE.COM, November 21, 2018 ) Catenin Beta 1 (Beta Catenin or CTNNB1)-Catenin beta-1 or β-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 5, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Download sample copy of this Report: http://www.reportsweb.com/inquiry&RW00012283721/buying
Scope
-The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
-The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
-The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics
Reasons to buy
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Get More Information about this Report: http://www.reportsweb.com/inquiry&RW00012283721/buying
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com